Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAC in Alzheimer's Disease or Vascular Dementia
NCT02886494Phase 2Completed
- Sponsor
- Charsire Biotechnology
- Start
- Dec 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of benzalkonium chloride in Alzheimer's disease (AD), vascular dementia, sponsored by Charsire Biotechnology. Started Dec 2016; status: completed.
02
Drugs
benzalkonium chloride
03
Conditions
Alzheimer's disease (AD)vascular dementia
Beyond the preview
Go deeper on NCT02886494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02886494.